Page last updated: 2024-08-21

quinazolines and Day Blindness

quinazolines has been researched along with Day Blindness in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Ahn, JS; Ahn, MJ; Chung, TY; Han, J; Jung, HA; Kang, WK; Lee, J; Lee, SH; Lim, DH; Nam, DH; Park, K; Shin, E; Sun, JM	1
Lee, HJ; Lee, JW	1
Bristow, E; Esmaeli, B; Faulkner, K; Forsythe, BJ; Murray, PI; Tullo, AB	1

Trials

1 trial(s) available for quinazolines and Day Blindness

Article	Year
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (London, England), 2005, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders	2005

Article

Year

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.

Eye (London, England), 2005, Volume: 19, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders

2005

Other Studies

2 other study(ies) available for quinazolines and Day Blindness

Article	Year
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC ophthalmology, 2020, Jan-09, Volume: 20, Issue:1 Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity	2020
Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma. Cutaneous and ocular toxicology, 2013, Volume: 32, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Finasteride; Glaucoma; Humans; Male; Middle Aged; Optic Neuropathy, Ischemic; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Vision Disorders	2013

Article

Year

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.

BMC ophthalmology, 2020, Jan-09, Volume: 20, Issue:1

Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity

2020

Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma.

Cutaneous and ocular toxicology, 2013, Volume: 32, Issue:2

Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Finasteride; Glaucoma; Humans; Male; Middle Aged; Optic Neuropathy, Ischemic; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Vision Disorders

2013